Biomarker Monitoring
Track biomarkers and research markers
Review status: Waiting for team review. An AI editorial check was completed on 2026-08-14 by claude-opus-5. It checks clarity, attribution and scope against the sources, and it is not a Compass team or clinical sign-off. Waiting for clinical review. Last updated 2026-08-14.
Items
Add an item
Saved on this device only. Never sent to us.
Simple ways to get started with this card. Use these as a checklist, add useful items to My Plan, or create your own.
Planning 3
- Clarify why this mattersAsk whether biomarkers would inform your care or are mainly for research.Why it matters: The answer changes whether this is something to pursue or simply something to know about.
- Identify what is availableAvailability varies considerably by clinic and by research access.Why it matters: Knowing what you can actually access keeps expectations grounded.
- Decide if tracking adds valueConsider whether the result would change a decision or is mainly informational.Why it matters: More data is only worth it if it leads somewhere, and monitoring has its own burden.
Your feedback on these suggested items
Are these useful starting items for Biomarker Monitoring? Reference an item by its title in your comment.
#
A biomarker is something that can be measured in the body and gives information about a condition. It might be measured in blood, spinal fluid, or through scans. In ALS/MND, biomarkers are a major focus of research, because better biomarkers could help in several ways.
What biomarkers could help with:
- Diagnosis. Potentially helping confirm ALS/MND earlier or more reliably.
- Tracking the condition. Measuring how it is changing over time.
- Testing treatments. Giving researchers a measurable signal of whether a treatment is having an effect, which can make trials faster and more sensitive.
- Understanding the condition. Helping researchers learn what is happening in the body.
- Grouping people. Potentially helping match people to treatments most likely to help them, as understanding grows.
An honest picture of where things stand:
- Biomarkers in ALS/MND are an active and promising area of research, but most are still being studied rather than being routine parts of everyday care.
- Some biomarkers are emerging into use, particularly within research and clinical trials, and the field is moving. It is important not to over-expect. (A clinician or researcher can explain what, if anything, is currently used in practice; this is changing over time.)
- ALS/MND is still mainly diagnosed and monitored clinically. That means assessment by your team, rather than a single test.
So the honest summary is: biomarkers are an exciting and fast-moving research area with real potential, but for most people today they are mostly relevant through research and trials rather than routine care. The next questions look at current versus research use, whether they could be relevant to you, and how to take part in biomarker research.
Explained: what this word meansEvidence for this answer
The sources the Compass team used to write this answer. Highlighted phrases in the answer above correspond to the statements below.
Statement 1 of 2. A biomarker gives researchers a measurable signal of whether a treatment is having an effect, which can let a trial show that in less time and in fewer people.
Supports this. Biomarker Qualification for Neurofilament Light Chain in ALS: Theory and Practice — Annals of Neurology · Research review · December 2023
Says the clinical measures ALS trials rely on are insensitive early in drug development, and that the benefit of using a fall in neurofilament light as a response measure is showing a biological response over a shorter time and in a smaller number of patients.
Link checked August 2026
Adds context. FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene — U.S. Food and Drug Administration · Official clinical information · April 2023
Not the basis for the sentence, but it shows what this looks like in practice. The US regulator approved an ALS treatment on the strength of a change in a biomarker rather than a change in how people were, on the understanding that the change is reasonably likely to predict a real benefit.
“Qalsody is approved under the accelerated approval pathway, under which FDA may approve drugs for serious conditions where there is an unmet medical need and a drug is shown to have an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients.”
EffectivenessLink checked August 2026
Statement 2 of 2. Most ALS/MND biomarkers are still being studied rather than used routinely in everyday care.
Qualifies this. Biomarker Qualification for Neurofilament Light Chain in ALS: Theory and Practice — Annals of Neurology · Research review · December 2023
Agrees no ALS biomarker has been formally qualified by the US regulator, and notes only eight biomarkers of any kind ever have been, none of them for a neurological condition. But it also says one marker, neurofilament light, is already firm enough that a treatment approval was based partly on it, so for that one marker the answer's picture is more cautious than the field's.
“Though NfL has not yet been formally qualified for any of these contexts-of-use, the FDA has provided accelerated approval for an SOD1-lowering antisense oligonucleotide, based partially on the recognition that a reduction in NfL is reasonably likely to predict a clinical benefit.”
Results.Link checked August 2026
Used across the whole answer
#
It helps to separate what biomarkers can do in research from what they currently do in everyday care, because the gap between the two is where unrealistic expectations can creep in.
Mostly research, for now:
- The majority of biomarker work in ALS/MND is still in the research phase. It is being studied to see whether it is reliable and useful, rather than being a standard part of routine care.
- Researchers use biomarkers heavily in clinical trials, where measuring a biological signal can help show whether a treatment is working.
- New biomarkers are actively being discovered and tested.
Emerging into use:
- Some biomarkers are beginning to be used in specialist and trial settings. The field is genuinely moving forward.
- One area that has drawn attention is markers measured in blood or spinal fluid that may reflect nerve-cell damage, which are being explored for tracking the condition and in trials. Exactly how and whether such markers are used in practice varies, and is best explained by your specialist team or a researcher.
Still mainly clinical:
- For most people, ALS/MND is still diagnosed and monitored through clinical assessment by your team, rather than by a single biomarker. That includes your symptoms, examination, and tests like breathing measures.
What this means for you:
- It is worth being interested but realistic. Biomarkers hold promise, but a single blood test that tells you everything about your ALS/MND does not yet exist in routine care.
- Be cautious of anyone offering "biomarker tests" privately that promise to diagnose, predict, or monitor your ALS/MND outside established medical or research settings. Check with your team first (the emerging therapies card covers evaluating such claims).
The honest, hopeful picture is of a field advancing steadily. The next question looks at whether biomarkers could be relevant to your care or trial options.
Explained: what this word meansEvidence for this answer
The sources the Compass team used to write this answer. Highlighted phrases in the answer above correspond to the statements below.
Statement 1 of 3. Markers measured in blood or spinal fluid that may reflect nerve-cell damage are being explored for tracking ALS/MND and are used in trials.
Supports this. Biomarker Qualification for Neurofilament Light Chain in ALS: Theory and Practice — Annals of Neurology · Research review · December 2023
The marker is neurofilament light, released when nerve fibres are damaged. The paper says the evidence supports using it to predict how ALS will progress, to see whether a treatment is having a biological effect, and as a safety signal. It is measured in blood and in spinal fluid, which track each other closely, and is used in many current ALS trials.
“For ALS, the body of scientific evidence supports its use as a prognostic, response, and potential safety biomarker in the broad ALS population, as well as a risk/susceptibility biomarker at least among a subset of SOD1 pathogenic variant carriers.”
IntroductionLink checked August 2026
Adds context. FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene — U.S. Food and Drug Administration · Official clinical information · April 2023
One concrete example rather than the basis for the whole sentence. It covers only the blood form of the marker and only its use in a trial, and says nothing about spinal fluid or about tracking the condition outside a trial.
“The approval was based on a reduction in plasma neurofilament light (NfL), a blood-based biomarker of axonal (nerve) injury and neurodegeneration.”
ActionLink checked August 2026
Statement 2 of 3. For most people, ALS/MND is monitored by repeated clinical assessment from their care team.
Supports this. NICE MND guideline — NICE · Clinical guideline
The UK guideline for MND builds monitoring entirely around repeated assessment by the multidisciplinary team, and lists the areas that team should assess and review, from swallowing and muscle problems to breathing and cognition. It recommends no biomarker test anywhere in its recommendations.
“Ensure that all healthcare professionals and social care practitioners involved in the person's care are aware that MND symptoms may get worse quickly, and that people with MND will need repeated, ongoing assessments.”
1.5.10Link checked August 2026
Statement 3 of 3. Biomarker tests offered privately, outside established medical or research settings, are worth treating with caution.
Adds context. Biomarker Qualification for Neurofilament Light Chain in ALS: Theory and Practice — Annals of Neurology · Research review · December 2023
Does not discuss private test sellers, so it is not the basis for the warning. It does establish the two facts behind it: the best developed ALS biomarker can already be ordered as a commercial laboratory test, and the authors say plainly that it can be misused if what it can and cannot tell you is not understood.
“NfL is currently available commercially as an orderable laboratory test; and a nuanced understanding of the pros and cons of using NfL for different purposes, will help to minimize the potential for its misuse.”
How might this potentially impact on the practice of neurology?Link checked August 2026
Used across the whole answer
#
Whether biomarkers are relevant to you right now depends on your situation, and especially on whether you take part in research or trials. Here is a realistic view.
In routine care:
- For most people, day-to-day ALS/MND care does not currently revolve around biomarkers. It is guided by clinical assessment and tests like breathing measures.
- That said, the picture is evolving, and your specialist team is best placed to tell you whether any biomarker testing is relevant or available in your care.
In clinical trials:
- Biomarkers are more likely to be relevant if you take part in a trial. Trials often:
- Measure biomarkers to track whether the treatment is having an effect.
- Use biomarkers in eligibility. For example, some trials focus on people with particular biological or genetic characteristics.
- This connects with the clinical trials and genetic testing cards. If you are exploring trials, biomarkers may be part of what is measured or assessed.
Questions worth bringing to your team:
- Is any biomarker testing relevant or useful in my care right now?
- Could biomarkers affect which trials I might be eligible for?
- If I join a trial, what biomarkers would be measured, and would I learn the results?
Setting expectations:
- It is reasonable to be curious and to ask. It is also realistic to expect that, for now, biomarkers are mostly a research tool rather than something that will change your routine care.
- Your team will tell you if and when a biomarker becomes relevant to your care, as the science develops.
The most useful approach is to stay interested, ask your team, and consider research participation if biomarkers (and contributing to progress) appeal to you. The next question covers how you could be involved in biomarker research.
Explained: what this word meansEvidence for this answer
The sources the Compass team used to write this answer. Highlighted phrases in the answer above correspond to the statements below.
Statement 1 of 2. Day-to-day ALS/MND care is guided by clinical assessment and by tests such as breathing measures.
Supports this. NICE MND guideline — NICE · Clinical guideline
The UK MND guideline describes exactly this. Recommendation 1.5.3 lists what the team should assess and review at each appointment, and 1.15.10 says breathing tests should be done every 2 to 3 months, more or less often depending on symptoms and how fast the condition is progressing.
Link checked August 2026
Statement 2 of 2. Some trials are open only to people who have a particular biological or genetic characteristic.
Supports this. FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene — U.S. Food and Drug Administration · Official clinical information · April 2023
Describes an ALS trial that did this. Everyone in it had to have a fault in the SOD1 gene, confirmed by a laboratory test, before they could take part, and the treatment it led to is licensed only for people with that same gene fault.
“The effectiveness of Qalsody was evaluated in a 28-week, randomized, double-blind, placebo-controlled clinical study in 147 patients with weakness attributable to ALS and a SOD-1 mutation confirmed by a central laboratory.”
EffectivenessLink checked August 2026
Used across the whole answer
#
If contributing to biomarker research appeals to you, there are several ways to be involved. Taking part helps move the whole field forward, which benefits everyone with ALS/MND.
Ways to take part:
- Through clinical trials. Many trials collect biomarker samples (such as blood or spinal fluid) as part of the study. If you join a trial, biomarker research may be part of it (see the clinical trials card).
- Through research registries and biobanks. Some registries and biobanks collect samples and information specifically to support biomarker and other research. Sometimes this involves relatively little burden (see the research registries card).
- Through studies run by your ALS/MND centre. Specialist centres often run their own research, including biomarker studies, that you may be able to join.
What involvement might mean:
- Giving samples. Usually blood; sometimes spinal fluid (via a lumbar puncture) or other samples, depending on the study. The study team will explain exactly what is involved and any discomfort or risks.
- Sharing information about your condition over time.
- Consent. As with all research, you would be given clear information and asked to consent, and you can withdraw at any time.
Things to consider:
- Weigh the burden. Some sampling (like spinal fluid) is more involved than a blood test; the team will explain what each study asks, so you can decide what suits you and your energy.
- Will you learn your results? Studies differ. In many, individual biomarker results are not given back to participants, because they are collected for research rather than for your personal care. Some studies do share some of your own data with you. Ask each study what to expect.
- Reputable settings only. Take part through established trials, registries, or your ALS/MND centre. Avoid unproven private "biomarker testing" offers.
How to start: ask your ALS/MND team or centre what biomarker research you could take part in, or explore registries (see that card). Your team can guide you to legitimate, worthwhile opportunities that fit your situation. The next question offers prompts to raise.
Explained: what this word meansEvidence for this answer
The sources the Compass team used to write this answer. Highlighted phrases in the answer above correspond to the statements below.
Statement 1 of 2. Taking part in research helps move ALS/MND research forward.
Supports this. ALS Observational Studies — Your ALS Guide · Practical guide
Sets out the chain this sentence is describing, for observational studies, which is the kind of study most biomarker research uses. It says taking part helps researchers learn what causes ALS and how it progresses, and that this in turn helps identify biomarkers and improve clinical trials. It does not cover taking part in a treatment trial.
“Observational studies help researchers learn more about ALS, including potential causes, its different types, and how it progresses.”
Why are observational studies so important?Link checked August 2026
Statement 2 of 2. Taking part in research means being given information and asked to consent, and being able to withdraw at any time.
Supports this. ALS Observational Studies — Your ALS Guide · Practical guide
Says every study requires you to sign an informed consent form setting out how your data will be used and how the team will protect it, and that taking part is voluntary and can be stopped. Written about observational studies rather than about every kind of research.
“Participation in observational studies is voluntary, so if needed, you can withdraw at any time.”
Is participation right for me?Link checked August 2026
Used across the whole answer
#
A few questions for your ALS/MND team or a researcher help you build a realistic picture of where biomarkers fit for you. Pick what interests you.
Understanding
- What are biomarkers, and are any used in my care at the moment?
- Is ALS/MND mainly monitored clinically for me, or are there tests that help?
- What is realistic to expect from biomarkers now, versus what is still research?
Relevance to me
- Could any biomarker testing be useful or available in my care?
- Could biomarkers affect which trials I might be eligible for?
- Is there any biomarker research you would suggest I consider?
Taking part in research
- What biomarker research or studies could I take part in?
- What would be involved (samples, visits), and what are any risks?
- Would I learn my own results, or are they only for research?
- Is it through a reputable trial, registry, or centre?
Checking claims
- I have seen a private "biomarker test" advertised. Is it legitimate and worth it? (Worth checking before paying. See the emerging therapies card.)
It is reasonable to be interested but realistic. Biomarkers are promising and advancing, but for now they mostly matter through research and trials. Your team can give you an honest, up-to-date picture for your situation. The clinical trials, research registries, and genetic testing cards cover closely related ground.
Explained: what this word meansLived experience
Practical tips and experiences shared by people affected by MND. These are not medical advice and may not apply to everyone.
No lived-experience tips for this card yet.
Resources
Your review of the resources
Are these useful, trustworthy, relevant and the right level? Anything missing, too regional, or better on another card?
Notes
Personal Planning Notes
Private to you. Saved on this device only, never sent to us.
Improve this card
A short overall review of this whole card. You can also give feedback on individual answers, resources and steps in their tabs.
Have a resource or a practical tip to share instead? Share what you have learned.